GALECTIN THERAPEUTICS INC — Director's Dealing 2018

Jun 8, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-06-06

Reporting Person: Shlevin Harold H. (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-06	Common Stock	M	4180	$2.32	Acquired	58094	Direct
2018-06-06	Common Stock	M	4898	$.87	Acquired	62992	Direct
2018-06-06	Common Stock	S	9078	$5.15	Disposed	53914	Direct
2018-06-07	Common Stock	M	75190	$2.32	Acquired	129104	Direct
2018-06-07	Common Stock	M	25701	$.87	Acquired	154805	Direct
2018-06-07	Common Stock	S	100891	$5.2063	Disposed	53914	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-06	Stock option (right to buy)	$2.32	M	4180	Disposed	2022-08-27	Common Stock (4180)	Direct
2018-06-06	Stock option (right to buy)	$.87	M	4898	Disposed	2026-12-03	Common Stock (4898)	Direct
2018-06-07	Stock option (right to buy)	$2.32	M	75190	Disposed	2022-08-27	Common Stock (75190)	Direct
2018-06-07	Stock option (right to buy)	$.87	M	25701	Disposed	2026-12-03	Common Stock (25701)	Direct

Footnotes

F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018.

F2: The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014.

F3: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017.

F4: The shares were sold in multiple transactions at prices ranging from $5.15 to $5.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.